One year follow up analysis of the phase 1a/b study of chimeric fibril-reactive monoclonal antibody 11-1F4 in patients with AL amyloidosis

Amyloid. 2019;26(sup1):115-116. doi: 10.1080/13506129.2019.1584892.

Authors

Affiliations

¹ a Department of Hematology and Oncology, Boston Medical Center , Boston , MA , USA.
² b Division of Hematology and Oncology, Columbia University Medical Center , New York , NY , USA.
³ c Division of Nephrology, Columbia University Medical Center , New York , NY , USA.
⁴ d Division of Cardiology, Columbia University Medical Center , New York , NY , USA.
⁵ e Graduate School of Medicine, University of Tennessee , Knoxville , TN , USA.

PMID: 31343323
DOI: 10.1080/13506129.2019.1584892

No abstract available

Publication types

Clinical Trial, Phase I
Multicenter Study

MeSH terms

Animals
Antibodies, Monoclonal / administration & dosage*
Antibodies, Monoclonal / adverse effects
Female
Humans
Immunoglobulin Light-chain Amyloidosis / drug therapy*
Male
Mice

Substances

Antibodies, Monoclonal